Fig. 6: Survival analysis in MCM8IP-deficient cells treated with cisplatin or olaparib.

a Survival analysis in HCT116 control cells or cells expressing the indicated MCM8IP sgRNAs upon treatment with cisplatin. Cell survival is expressed as a percentage of an untreated control. The mean ± SD of three independent experiments is presented. Statistical analysis was conducted on data points at three distinct cisplatin concentrations (0.625, 0.313, 0.156 µM) using Student’s t-test (**p < 0.01, at all three concentrations, two-tailed). b Detection by western blot of MCM8IP in HCT116 control cells or cells expressing the indicated MCM8IP sgRNAs utilized in the assay shown in (a). Tubulin is shown as a loading control. c Survival analysis of cisplatin-treated HCT116 control cells or cells expressing the indicated sgRNAs. Cell survival is shown as in (a). The mean ± SD of three or more independent experiments (n = 3–4) is presented. Statistical analysis was conducted as in (a) (***p < 0.001, at all three concentrations analyzed). d Survival analysis of HCT116 control cells or an HCT116 MCM8IP KO clone in response to cisplatin. Cell survival is represented as in (a). The mean ± SD of three independent experiments is presented. Statistical analysis was conducted as in (a) (**p < 0.01, at all three concentrations analyzed). e Survival analysis in the HCT116 MCM8IP KO clone shown in (g) reconstituted with MCM8IP WT, MBM #2, or an empty vector (EV) control in response to cisplatin. Cell survival is shown as in (a). The mean ± SD of four independent experiments is presented. Statistical analysis was conducted as in (a) (**p < 0.01, ***p < 0.001, at all three concentrations analyzed). f Survival analysis in the HCT116 MCM8IP KO clone shown in (g) reconstituted with MCM8IP WT, MBM #2, or an EV control in response to olaparib. Cell survival is represented as in (a). The mean ± SD of three independent experiments is presented. Statistical analysis was conducted on data points at three distinct olaparib concentrations (0.313, 0.156, 0.078 µM) as in (a) (*p < 0.05, at all three concentrations). g Detection by western blot of MCM8IP in HCT116 control cells or in an MCM8IP KO clone (left panel), and in the same MCM8IP KO clone reconstituted with MCM8IP WT, MBM #2, or an EV control (right panel). Tubulin is shown as a loading control. h Detection by western blot of MCM8IP in an HCT116 MCM8IP KO clone reconstituted with MCM8IP WT, RBM, or an EV control. Vinculin is shown as a loading control. Asterisk indicates a non-specific band. i Survival analysis in the HCT116 MCM8IP KO clone shown in (h) reconstituted with MCM8IP WT, RBM, or an EV control in response to cisplatin. Cell survival is shown as in (a). The mean ± SD of nine independent experiments is presented. Statistical analysis was conducted as in (a) (*p < 0.05, ****p < 0.0001, at all three concentrations analyzed).